Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) (Q33401001)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) |
scientific article |
Statements
1 reference
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) (English)
1 reference
David P Steensma
1 reference
Guillermo Garcia-Manero
1 reference
Azra Raza
1 reference
Naomi Galili
1 reference
Deborah Mulford
1 reference
Scott E Smith
1 reference
Gail L Brown
1 reference
Roger M Lyons
1 reference
Ralph Boccia
1 reference
Mikkael A Sekeres
1 reference
Ruben A Mesa
1 reference
1 reference
30 April 2012
1 reference
1 reference
Identifiers
1 reference
1 reference